GlassScriptPhysician profile
Amandeep Pal
NPI 1467694703
$3,359.94
in general payments reported to CMS, 2019-2025
26 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Geriatric Medicine (Family Medicine) provider received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $522 · 2021: $336 · 2022: $256 · 2023: $661 · 2024: $623 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,795.63 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $213.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $181.11 | 2019-2025 | |
| Boston Scientific Corporation | $130.26 | 2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $99.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $93.79 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $92.96 | 2021-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $91.29 | 2023-2025 | Rexulti |
| Insulet Corporation | $77.80 | 2024-2025 | Omnipod |
| Abbvie INC. | $65.95 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $61.26 | 2023 | Spravato |
| Exact Sciences Corporation | $51.49 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $43.02 | 2022-2024 | Capvaxive |
| Phathom Pharmaceuticals, INC. | $38.95 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $37.08 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $35.23 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.21 | 2024 | Tradjenta, Jardiance, Synjardy |
| Abbott Laboratories | $34.69 | 2024 | Octrode |
| Axsome Therapeutics, INC. | $32.02 | 2025 | Auvelity |
| Silk Road Medical, INC. | $30.07 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Allergan, INC. | $24.77 | 2020 | |
| Xeris Pharmaceuticals, INC. | $23.51 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.65 | 2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.27 | 2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $16.10 | 2023 | Jornay Pm |
| Amarin Pharma, INC. | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amandeep Pal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.